Kodiak Sciences (KOD) Total Current Liabilities (2017 - 2026)
Kodiak Sciences' (KOD) quarterly Total Current Liabilities came in at $49.6 million in Q1 2026, up 60.56% YoY from $30.9 million in Q1 2025, and up 8.87% on a QoQ basis from $45.5 million in Q4 2025.
Kodiak Sciences (KOD) Total Current Liabilities (2017 - 2026) Analysis & Trends
Kodiak Sciences (KOD) has 10 years of Total Current Liabilities data on file, last reported at $49.6 million in Q1 2026.
- Quarterly Total Current Liabilities rose 60.56% year-over-year to $49.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.6 million (up 60.56% YoY) and the FY2025 annual result came in at $45.5 million, up 78.05% from the prior year.
- Total Current Liabilities rose to $49.6 million in Q1 2026, from $45.5 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $76.3 million in Q1 2022 to a low of $21.2 million in Q2 2024.
- A 5-year average of $47.9 million and a median of $45.5 million in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities soared 117.74% — and 2024, when it tumbled 71.44%.
- Tracing KOD's Total Current Liabilities over 5 years: stood at $52.5 million in 2022, then decreased by 20.51% to $41.7 million in 2023, then sank by 38.72% to $25.6 million in 2024, then soared by 78.05% to $45.5 million in 2025, then rose by 8.87% to $49.6 million in 2026.
- The last three Total Current Liabilities figures came in at $49.6 million (Q1 2026), $45.5 million (Q4 2025), and $42.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Kodiak Sciences | 2.60 Bn | 2.60 Bn | - | 52.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 52.77 Mn |
| Mar 31, 2026 | 49.57 Mn |
| Dec 31, 2025 | 45.53 Mn |
| Sep 30, 2025 | 42.43 Mn |
| Jun 30, 2025 | 31.01 Mn |
| Mar 31, 2025 | 30.88 Mn |
| Dec 31, 2024 | 25.57 Mn |
| Sep 30, 2024 | 24.06 Mn |
| Jun 30, 2024 | 21.20 Mn |
| Mar 31, 2024 | 24.86 Mn |
| Dec 31, 2023 | 41.73 Mn |
| Sep 30, 2023 | 70.77 Mn |
| Jun 30, 2023 | 74.24 Mn |
| Mar 31, 2023 | 68.94 Mn |
| Dec 31, 2022 | 52.50 Mn |
| Sep 30, 2022 | 65.60 Mn |
| Jun 30, 2022 | 69.83 Mn |
| Mar 31, 2022 | 76.33 Mn |
| Dec 31, 2021 | 64.68 Mn |
| Sep 30, 2021 | 54.40 Mn |